In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.

Strategy India

Celgene Axes $55m Settlement On Drug Monopoly Claims

Astounding plaintiffs, Celgene has backed out of a $55m settlement of a class-action lawsuit which accused the company of monopolizing the market for two top-selling cancer drugs and depriving patients of cheaper generic versions.

Legal Issues Generic Drugs

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

Vaccines Infectious Diseases

India Bars Four Firms On Apixaban

The High Court of Delhi has issued a temporary injunction blocking four Indian drug-makers from launching generic versions of Bristol-Myers’ top-selling anticoagulant apixaban.

Legal Issues Intellectual Property

Outlook Positive For Indian Firms In 2020

Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.

Market Intelligence Generic Drugs

Strides’ New CEO Is Former Cipla COO

Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.

Appointments Strategy
See All
UsernamePublicRestriction

Register